Sacubitril/valsartan instead of renin‐angiotensin system inhibition alone: A step forward in resistant hypertension

E-ISSN： 1751-7176|20|1|65-68

ISSN： 1524-6175

Source： The Journal of Clinical Hypertension, Vol.20, Iss.1, 2018-01, pp. : 65-68

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Benefits and pitfalls of sacubitril/valsartan treatment in patients with hypertension

The Journal of Clinical Hypertension, Vol. 20, Iss. 2, 2018-02 ,pp. : 351-355

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double‐blind, 8‐week study

The Journal of Clinical Hypertension, Vol. 20, Iss. 1, 2018-01 ,pp. : 150-158

John Wiley & Sons Inc

Access to resources Recommend Favorite

Patients With Newly Diagnosed Hypertension Treated With the Renin Angiotensin Receptor Blocker Azilsartan Medoxomil vs Angiotensin‐Converting Enzyme Inhibitors: The Prospective EARLY Registry

The Journal of Clinical Hypertension, Vol. 17, Iss. 12, 2015-12 ,pp. : 947-953

John Wiley & Sons Inc

Access to resources Recommend Favorite

Resistant hypertension: a therapeutic challenge

The Journal of Clinical Hypertension, Vol. 20, Iss. 1, 2018-01 ,pp. : 76-78

John Wiley & Sons Inc

Access to resources Recommend Favorite

Additivity of nebivolol/valsartan single‐pill combinations versus other single‐pill combinations for hypertension

The Journal of Clinical Hypertension, Vol. 20, Iss. 1, 2018-01 ,pp. : 143-149

John Wiley & Sons Inc

Access to resources Recommend Favorite